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Abstract. Two novel potentially bioactive compounds, esters 2-methyl-1-phenylpyridine-4-one-3-yl 
adamantan-1-ylethanoate (1) and 1-(p-methoxyphenyl)-2-methylpyridine-4-one-3-yl adamantan-1-
ylethanoate (2), were synthesized by esterification of adamantan-1-ylacetic acid with appropriate N-aryl 
substituted 3-hydroxypyridine-4-one derivatives. Both compounds are fully characterized using standard 
spectroscopic methods. Crystal and molecular structures of 1 and 2 were determined by the single crystal 
X-ray diffraction method. The crystal packing of both 1 and 2 shows separation of the hydrophobic and 
hydrophilic regions. The crystal structure of 1 is characterized by the two-dimensional hydrogen bonding 
layers parallel to (001). The crystal packing of 2 is characterized by hydrogen-bonded chains extended in 
the direction [010].(doi: 10.5562/cca2339) 




3-Hydroxypyridine-4-ones (3,4-HPOs) are a family of 
heterocyclic compounds with nitrogen atom in the ring 
and hydroxyl and keto groups at positions 3 and 4, re-
spectively (Figure 1). The presence of the latter two 
functionalities allows them to exhibit their excellent 
chelating properties especially towards M(II) / M(III) 
metal ions.1−5 In therapeutic applications 3,4-HPOs are 
primarily used as potential sequesters of metal ions in 
various diseases that can cause metal overload6,7 as well 
as in such conditions that are elicited by metal poison-
ing.8 Furthermore, it has been shown that these ligands 
present their highest affinity for metal ions under physi-
ological conditions in which they are quite stable, non-
toxic and even resistant to enzyme-catalyzed cleavage. 
Variation of substituents at positions 1, 2, 5 and 
even at position 3 can strongly influence their biological 
activity. For example, several 3,4-HPOs glycosylated at 
position 3 have shown great promise for developing 
multifunctional treatment for Alzheimer's disease.8−11 
Incorporation of an adequate substituent at a position 
responsible for pyridine-4-ones chelating ability, in 
order to increase their solubility and improve pharma-
cokinetics, can temporarily mask the metal binding site 
and make these compounds useful and effective 
prodrugs.9−12 
Adamantyl based compounds are used clinically 
primarily for the treatment of neurological conditions, 
as antiviral and antitumor agents and potential drugs 
against type 2 diabetes.13,14 In almost all cases com-
pounds that bear the bulky adamantyl group tend to be 
more lipophilic than their des-adamantyl analogues. 
Furthermore, this group can modulate therapeutic activi-
ty of many experimental drugs and prodrugs by varying 
their mechanism of action.13 These are certaintly good 
enough reasons for its incorporation in any potential or 
already biologically active compound. 
Given the fact that the structure and function are 
closely related one can only benefit from the obtained 
X-ray structure data of potential drugs or prodrugs. The 
 
Figure 1. General structure of 3,4-HPO derivatives. 
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detailed structure of such compounds can provide ex-
tremely useful information that can be subsequently 
used in elucidation of their mechanism of action. Ac-
cording to the Cambridge Structural Database, CSDB,15 
a search using the ConQuest Version 1.15, gave only 22 
structures containing the adamantan-1-ylacetyl unit yet 
no structures which contain both adamantan-1-ylacetyl 
and 3,4-HPO units. 
We have prepared two adamantyl modified 3,4-
HPOs which are currently used in our ongoing biologi-
cal study on similar 3,4-HPO derivatives. Preliminary 
tests have shown that these compounds possess a bio-
logical potential.16 Pyridinone esters of adamantan-1-
ylacetic acid were prepared in Steglich esterification 
conditions.17 Crystal and molecular structures of both 




Synthesis of Adamantan-1-ylacetic Acid Pyridinone 
Esters 
Materials and Methods 
The chemical reagents used in syntheses were obtained 
from Fluka or Aldrich Corp. All solvents were purified 
using standard procedures. Column chromatography 
(solvents and proportions are given in the text) of prod-
ucts were performed on Merck silica gel 60 (size 70–
230 mesh ASTM) and thin layer chromatography moni-
toring (TLC) on Fluka silica gel (60 F 254) plates (0.25 
mm). Visualization was effected by the use of UV light 
at 254 nm. Melting points were determined in open 
capillaries using Büchi B-540 melting point apparatus 
and are uncorrected. IR spectra were recorded using 
Perkin Elmer FT-IR Spectrometer Spectrum Two. 1H 
and 13C NMR spectra were recorded with Bruker 
Avance spectrometer at room temperature at 300.130 
MHz and 75.468 MHz, respectively. Chemical shifts are 
given in ppm downfield from TMS as internal standard. 
Electrospray ionization mass spectrometry (ESI-MS) 
was performed using Agilent 6410 MS instrument. 
CHN elemental analyses were carried out by the Analyt-
ical Service Laboratory of the Ruđer Bošković Institute. 
 
General Procedure 
An appropriate pyridinone derivative (0.5 mmol) was 
added to a solution of adamantan-1-ylacetic acid (95 mg, 
0.5 mmol) in dry CH2Cl2 (3 mL), N,N-dimethylami-
nopyridine (DMAP; 6 mg, 0.05 mmol). The mixture was 
cooled down to 0 °C and 1-ethyl-3-(3-dimethyaminopro-
pyl)carbodiimide hydrochloride (EDCHCl; 105 mg, 0.55 
mmol) was added next. The solution was stirred for 30 
min at 0 °C and subsequently 24 h at room temperature. 
The reaction was monitored by TLC (ethyl acetate / 
methanol 5:2). Dichloromethane was added and the or-
ganic layer was washed twice with 0.5 M HCl, then with 
saturated aqueous NaHCO3 solution and finally dried 
over MgSO4. After filtration, the organic extract was 
concentrated in vacuo. The residue was purified by col-
umn chromatography on silica gel (ethyl acetate / metha-
nol 5:2) giving the corresponding ester, 1 or 2. 
2-Methyl-1-phenylpyridine-4-one-3-yl adamantan-1-
ylethanoate (1): White crystals (125 mg, 67 %); Rf = 0.49 
(ethyl acetate / methanol 5:2); m.p. 184.5–185.8 ºC 
(decomp). IR (KBr) vmax / cm−1: 3044, 3005 (C−Harom.), 
2901 (C−Hs), 2847 (C−Has), 1748 (C=O, ester), 1645 
(C=O, ketone), 1497 (C=Carom.), 1286 (C−N), 1160 
(C−O, ester). 1H NMR (DMSO-d6) δ (ppm): 1.65 (br s, 
6H, 3 H-Ad), 1.72 (m, 6H, 3 H-Ad), 1.91 (s, 3H, CH3), 
1.94 (s, 3H, 3 H-Ad), 2.30 (s, 2H, CH2), 6.24 (d, 1H, J = 
7.6 Hz, H-5), 7.48–7.51 (m, 2H, H-Ar), 7.54–7.60 (m, 
3H, H-Ar), 7.69 (d, 1H, J = 7.5 Hz, H-6). 13C NMR 
(DMSO-d6) δ (ppm): 14.20 (CH3), 27.92 (C-Ad), 32.38 
(C-Ad), 36.13 (C-Ad), 41.40 (C-Ad), 47.51 (CH2), 
115.39 (C-5), 127.04 (2 CH-Ar), 129.31 (CH-Ar), 129.75 
(2 CH-Ar), 139.13 (C-3), 140.15 (C-2), 140.71 (C-6), 
141.03 (C−N), 167.79 (C=O, ester), 169,56 (C=O). ESI-
MS: m/z [M+H]+ 378.3. Anal. Calcd. mass fraction of 
elements, w / %, for C24H27NO3 (Mr = 377.48)  are: C 
76.36, H 7.21, N 3.71, found: C 76.26, H 7.27, N 3.75. 
1-(p-Metoxyphenyl)-2-methylpyridine-4-one-3-yl 
adamantan-1-ylethanoate (2): White crystals (61 mg, 
59 %); Rf = 0.6 (ethyl acetate / methanol 5:2); m.p. 
196.6–197.7 ºC. IR (KBr) max / cm−1: 3066, 3049 
(C−Harom.), 2907 (C−Hs), 2845 (C−Has), 1752 (C=O, 
ester), 1638 (C=O, ketone), 1511 (C=Carom.), 1287 
(C−N), 1243 (C−O−C, ether), 1154 (C−O, ester). 1H 
NMR (DMSO-d6) δ (ppm): 1.65 (s, 6H, 3 H-Ad), 1.72 
(s, 6H, 3 H-Ad), 1.90 (s, 3H, CH3), 1.95 (s, 3H, 3 H-
Ad), 2.29 (s, 2H, CH2), 3.83 (s, 3H, OCH3), 6.21 (d, 1H, 
J = 7.6 Hz, H-5), 7.09 (d, 2H, J = 8.9 Hz, H-Ar), 7.4 (d, 
2H, J = 8.8 Hz, H-Ar), 7.63 (d, 1H, J = 7.6 Hz, H-6). 
13C NMR (DMSO-d6) δ (ppm): 14.10 (CH3), 27.90 (C-
Ad), 32.32 (C-Ad), 36.11 (C-Ad), 41.38 (C-Ad), 
47.48 (CH2), 55.43 (OCH3), 114.65 (2 CH-Ar), 115.24 
(C-5), 128.19 (2 CH-Ar), 133.89 (C−N), 139.02 (C-3), 
140.53 (C-2), 140.97 (C-6), 159.38 (C-Ar), 167.74 
(C=O, ester), 169.49 (C=O). ESI-MS: m/z [M+H]+ 
408.2. Anal. Calcd. mass fraction of elements, w / %, for 
C25H29NO4 (Mr = 407.50) are: C 73.68, H.7.17, N 3.44, 
found: C 73.80, H 7.01, N 3.47. 
 
X-ray Crystallography 
The single-crystal X-ray diffraction data of 1 and 2 were 
collected by -scans on an Oxford Diffraction Xcalibur 
3 CCD diffractometer with graphite-monochromated 
Mo-K radiation ( = 0.71073 Å). Data reduction was 
performed using the CrysAlis software package.18 Solu-
tion, refinement and analysis of the structures were done 
using the programs integrated in the WinGX system.19 
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The structures were solved using SHELXS by direct 
methods. The refinement procedure was performed by 
the full-matrix least-squares method based on F2 against 
all reflections using SHELXL.20 The non-hydrogen 
atoms were refined anisotropically. All hydrogen atoms 
were located in the difference Fourier maps and refined 
isotropically. Exceptions were hydrogen atoms on atom 
C18 (methyl group) in 2 which were placed in calcu-
lated positions and refined using the riding model. Ge-
ometrical calculations were done using PLATON. 21 The 
structure drawings were prepared using the MERCURY 
program.22 Crystallographic and structure refinement 
data for 1 and 2 are summarized in Table 1, whereas the 
selected bond distances and angles are listed in Table 2. 
 
RESULTS AND DISCUSSION 
Synthesis 
Two different N-aryl substituted 3,4-HPOs, namely 3-
hydroxy-2-methyl-1-phenylpyridine-4-one and 3-
hydroxy-1-(p-methoxyphenyl)-2-methylpyridine-4-one, 
were used as an alcohol component in the esterification 
of adamantan-1-ylacetic acid (Scheme 1). Both 
pyridinone derivatives were synthesized following the 
procedure reported by Jakopčić et al.2 The incorpora-
tion of adamantyl moiety into 3,4-HPO structures was 
carried out in mild Steglich esterification conditions in 
the presence of coupling carbodiimide reagent and a 
catalytic amount of N,N-dimethylaminopyridine 
(DMAP).17 
As 1-ethyl-3-(3-dimethyaminopropyl)carbodii-
mide hydrochloride (EDC·HCl) was used as the cou-
pling reagent, a byproduct, water soluble urea, can be 
easily removed by extraction and does not contami-
nate the product. After column chromatography puri-
fication, pyridinone esters of adamantan-1-ylacetic 
acid, 2-methyl-1-phenylpyridine-4-one-3-yl adaman-
tan-1-yl-ethanoate (1) and 1-(p-methoxyphenyl)-2-
methylpyridine-4-one-3-yl adamantan-1-ylethanoate 
(2) were isolated in good yields, 67 % and 59 %, re-
spectively. Both compounds were characterized using 
Table 1. Crystallographic data and structure refinement details for compounds 1 and 2 
 1 2 
chemical formula  C24H27NO3  C25H29NO4 
   
Mr 377.47 407.49 
crystal colour, habit colourless, plate colourless, plate 
crystal dimensions/ mm 0.58×0.48×0.08 0.47×0.33×0.15 
crystal system triclinic monoclinic 
space group P-1 C 2/c 
unit cell parameters   
a/ Å 6.9482(4) 25.669(2) 
b/ Å 9.1811(5) 9.9870(3) 
c/ Å 15.6785(8) 22.2003(18) 
α, β, γ / ° 96.302(4), 100.405(4), 957.59(9) 90, 132.283(14), 90 
V/ Å3 957.59(9) 4210.5(11) 
Z 2 8 
Dcalc/ g cm−3 1.309 1.286 
temperature/ K 150(2) 295(2) 
wavelength/ Å 0.71073 0.71073 
μ / mm−1 0.086 0.086 
F(000) 404 1744 
number of unique data  3758 3702 
number of data [Fo ≥ 4σ(Fo)] 2999 2842 
number of parameters 361 375 
R1a, [Fo ≥ 4σ(Fo)] 0.038 0.050 
wR2b 0.104 0.127 
Goodness of fit on F2, Sc 1.05 1.04 
Δρmax,Δρmin (e Å−3) −0.17, 0.23 −0.20, 0.29 
       1/ 2 1/ 22 2 2a b 2 2 2 c 2 2o c o o c o o c obs param; ;R F F F wR F F w F S w F F N N                     
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standard spectroscopic methods, electrospray ioni-
zation mass spectrometry and X-ray structural analy-
sis. 
X-ray Crystallography 
The molecular geometry, as determined by X-ray analy-
sis, and the atom labelling scheme of 1 and 2 are shown 
in Figure 2. Differences in the molecular structure of the 
1 and 2 are revealed by their overlay (Figure 3), the 
greatest being at the methoxy group in 2, and by dihe-
dral angles between the pyridinone and phenyl rings. 
Analysis of the bond lengths revealed only small or 
insignificant differences in the molecular structure of 1 
and 2 (Table 2). 
The adamantane unit in 1 and 2 consists of four 
cyclohexanes fused with each other, all approaching the 
ideal chair conformations. The values of the bond 
lengths and angles in the adamantane unit are similar to 
those found in other related compounds.23−25 The six-
membered pyridinone and phenyl rings in both 1 and 2 
Table 2. Selected bond lengths (Å) and angles () for com-
pounds 1 and 2 
 1 2 
O1−C1 1.2015(17) 1.194(3) 
O2−C1 1.3621(17) 1.364(4) 
O1−C13 1.4061(16) 1.403(3) 
O3−C14 1.2516(15) 1.244(2) 
N1−C19 1.4484(16) 1.451(2) 
C1−C2 1.5009(19) 1.497(5) 
C2−C3 1.5442(18) 1.541(3) 
C3−C4 1.540(2) 1.525(3) 
C3−C10 1.5384(19) 1.530(6) 
C3−C11 1.538(2) 1.522(5) 
C1−O2−C13 115.92(10) 116.30(17) 
C16−N1−C17 119.28(11) 119.68(17) 
C16−N1−C19 118.98(11) 119.4(2) 
C17−N1−C19 121.63(11) 120.8(2) 
O1−C1−O2 123.09(12) 122.3(3) 
O1−C1−C2 125.63(13) 126.0(3) 
O2−C1−C2 111.28(12) 111.7(2) 
C1−C2−C3 113.89(11) 114.7(3) 
C4−C3−C10 108.64(11) 109.6(3) 
C4−C3−C11 108.40(11) 107.3(3) 
C21−C22−C23 119.78(14) 120.25(19) 
 
Scheme 1. Synthesis of adamantyl derivatives of 3,4-HPOs. 
 
Figure 2. a) The ORTEP drawing of 1. b) The ORTEP drawing of 2. Ellipsoids are shown at the 50% probability and hydrogen
atoms are shown as spheres of arbitrary radii. 
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are planar with the dihedral angles between the two 
planes 78.39(13)  and 60.95(7) , respectively. 
In the previously reported structure of 1-(p-me-
thoxyphenyl)-3-hydroxy-2-methyl-4-pyridinone (Hpap) 
the pyridinone ring is slightly nonplanar and the  
phenyl ring is planar. The dihedral angle between the 
two planes is 73.7 , which is quite different than in 
2.26 The pattern of the bond lengths within the 
pyridinone and phenyl rings in 2 is similar to that ob-
served in the Hpap molecule. Exception is a longer 
O2C13 bond (1.403(3) Å in 2 and 1.357(2) Å in 
Hpap). 
Table 3. Geometry of intermolecular hydrogen bonds (Å, ) for compounds 1 and 2 
 DH···A DH / Å H···A / Å D···A / Å DH···A /  
1 C15H15···O1i 0.983(15) 2.580(15) 3.1877(17) 120.1(11) 
 C16H16···O1i 0.970(14) 2.659(14) 3.1971(17) 114.4(12) 
 C20H20···O3i 0.967(15)   2.315(15) 3.2689(17)   168.8(12) 
 C24H24···O3ii 0.958(15)   2.383(15) 3.2087(17)   144.2(12)    
 C18H18C···O2 0.964(18) 2.423(17) 2.7931(18) 102.4(12) 
    2     C15H15···O1iii     0.95(2)     2.71(3)     3.291(4)     120.2(11) 
     C20H20···O3iii        0.96(2)     2.47(2)     3.348(3)     152(3) 
     C21H21···O3iv     0.96(2)     2.66(2)     3.600(4)     168(2) 
i 2 − x, 1 − y, 1 − z; ii 1 − x, 1 − y, 1 − z; iii 2 − x, 1 − y, −z; iv x, −1 + y, z. 
 
Figure 3. Superposition of the molecules of 1 and 2. 
 
Figure 4. The crystal packing of 1: a) Partial structural motif of the two-dimensional hydrogen bonding network, layers parallel to
(001) (hydrogen atoms that are not participating in intermolecular hydrogen bonds including the intramolecular C18H18C···O2
hydrogen bond are omitted for clarity). Hydrogen-bonds are shown by blue dotted lines. b) Weak CH···O hydrogen bonds
(C15−H15···O12−x,1−y,1−z 3.1877(17) Å, C16H16···O12−x,1−y,1−z 3.1971(17) Å, C20−H20···O32−x,1−y,1−z 3.2689(17)
Å and C24−H24···O3 1−x,1−y,1−z 3.2087(17) Å). Hydrogen-bonds are shown by blue dotted lines. 
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There are no classical hydrogen bonds in the crys-
tal structures of 1 and 2, however weak intermolecular 
C−H∙∙∙O hydrogen bonds are present (Table 3). The X-
ray structure of 1 also reveals an intramolecular hydro-
gen bond C18−H18C∙∙∙O2 (Table 3). The crystal pack-
ing of both 1 and 2 shows separation of the hydrophobic 
and hydrophilic regions. In 1 the hydrogen bonds con-
nect the molecules into layers parallel to (001) (Figure 
4a). Hydrogen bonds in 1 involve double acceptors, the 
ester carbonyl oxygen atom (O1) and the keto group 
oxygen atom from the pyridinone moiety (O3). C and H 
atoms from the phenyl (C20 and C24) and from the 
pyridinone ring (C15 and C16) serve as hydrogen bond 
donors (Figure 4b). The crystal packing of 2 is charac-
terized by hydrogen-bonded chains extended in the 
direction [010] (Figure 5a). Hydrogen bonds in 2 in-
volve a double acceptor function of the keto group oxy-
gen atom O3 and donors from the aromatic C20−H20 
and C21−H21 atoms. Additionaly, the ester carbonyl 
oxygen atom (O1) serves as the hydrogen bond acceptor 
and C15−H15 from the pyridinone unit as the hydrogen 
bond donor (Figure 5b). 
 
CONCLUSION 
Two pyridinone esters of adamantan-1-ylacetic acid 
were prepared in satisfactory yields. The procedure 
involved mild Steglich esterification in which two N-
aryl substituted 3,4-HPO derivatives were used as the 
alcohol part. The final pyridinones 1 and 2 bearing the 
adamantyl moiety were fully characterized by standard 
spectroscopic methods and also by the X-ray structural 
analysis. The crystal packing of both 1 and 2 shows 
separation of the hydrophobic and hydrophilic regions. 
There are no classical hydrogen bonds in the crystal 
structures of 1 and 2, however weak intermolecular 
C−H∙∙∙O hydrogen bonds are present. The crystal pack-
ing of 1 is characterized by the hydrogen bonds con-
necting molecules into layers parallel to (001) while the 
crystal packing of 2 is characterized by hydrogen-
bonded chains extended in the direction [010]. 
Supplementary Materials. – CCDC 950307 and 950308 con-
tain the supplementary crystallographic data for this paper. 
These data can be obtained free of charge via 
www.ccdc.cam.ac.uk/data request/cif, or by e-mailing to data 
request@ccdc.cam.ac.uk, or by contacting The Cambridge 
Crystallographic Centre, 12, Union Road, Cambridge CB2 
1EZ, UK; fax: +44 1223 336033. 
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